Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
about
Erythropoietin in the critically ill - is it more than just blood?Oxidative stress: Biomarkers and novel therapeutic pathways.Erythropoietin after a century of research: younger than ever.High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusionErythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways.New avenues of exploration for erythropoietin.Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitusErythropoietin: elucidating new cellular targets that broaden therapeutic strategiesMechanistic insights into diabetes mellitus and oxidative stressErythropoietin and oxidative stress.Blood management: a primer for clinicians.Safety of intravitreally administered recombinant erythropoietin (an AOS thesis)Circulating levels of erythropoietin and its relation to arterial stiffness in patients with hypertensionHuman erythropoietin gene delivery for cardiac remodeling of myocardial infarction in ratsG-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction.Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling.Development of novel drug delivery systems using phage display technology for clinical application of protein drugsCorrection of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.Erythropoietin and the heart: facts and perspectives.Erythropoietin: a hormone with multiple functions.Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility.Huh-7 cell line as an alternative cultural model for the production of human like erythropoietin (EPO).Erythropoietin induced tumour mass reduction in murine lymphoproliferative models.Systemic and renal haemodynamic changes in renal schemia/reperfusion injury: impact of erythropoietin.
P2860
Q24800397-5D33D23A-DE68-4F66-9992-5042F3ABB563Q33682262-8BE74DF9-6A25-40D4-AA55-A2B692236E1EQ34606348-0C85A466-FCD8-41F0-83A2-923D21505CD9Q35008662-5762FA47-9CAF-4104-B03D-E12226B18FA5Q35193649-00394620-F1A1-411E-AFD1-1AA8BFD5EEBFQ35997721-BE16CC00-D390-4185-BEE5-00796B66873AQ35999785-4EDDF563-85F0-4B42-9BCB-F9B7EB83FF00Q36663152-60776839-1C47-4B78-9EDD-8A0FC8D50A74Q36740470-1D82A7B6-5D87-4BF2-9F21-F9D16F63F1C7Q36748171-6B500B8F-F1D0-450C-8E97-EE655E9ACEA9Q36944477-EF83A86A-EF55-427C-84D7-D0DC7C704318Q36951995-C27AE203-6C4C-4A91-B8EA-7D3F950929C7Q37106306-0FDDF9A3-89A5-4B6C-8779-4ACD1CF8483CQ37146335-5550EE9E-B6F5-4302-A6B3-0B08E5D2C43BQ37158904-5B723661-5434-4E2D-A41F-C2521102B0E8Q37176449-284699A3-613F-4663-ABBB-DD3F224DECE7Q37182044-38FB2BE6-0EA6-4F27-A513-9F5E7D25C58EQ37198453-12605F6A-F7BB-46AA-A00C-A692E273EFD4Q37473690-01BF02C0-42BC-4AC9-B658-115286E92ABEQ37798565-4E132EA7-5F27-4E4A-AFD7-FF09AC54E652Q37862940-7877835C-EE87-415E-8EE4-117CBA8CFE23Q38432879-49E03558-FA13-4D0B-899B-E6F22B592D42Q39450330-F602F3CC-CE43-4EE6-87A4-C80467E0210CQ40361336-B577FD68-C829-43F8-B513-F90AF32E009BQ46402870-C105AF5D-D309-4ED1-85E4-1B87DCB9F4AB
P2860
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@ast
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@en
type
label
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@ast
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@en
prefLabel
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@ast
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@en
P2093
P1476
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
@en
P2093
David H Henry
Michael T Romano
Peter Bowers
Robert Provenzano
P304
P356
10.1001/ARCHINTE.164.3.262
P407
P577
2004-02-01T00:00:00Z